Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, as well as improving mRNA vaccines.
It has three active drug development programs: two innovative technology platforms – Sofra™ (mRNA vaccines, inflammation and autoimmunity) and Chroma™ (oncology) which provide the basis for active development of a growing pipeline of new proprietary drugs, as well as its clinical drug candidate Veyonda®.
The company has unique proprietary technology aimed at making mRNA vaccines safer to take by reducing side effects while reducing manufacturing costs for vaccine producers.
Noxopharm also has a major shareholding in the US biotech company Nyrada Inc (ASX:NYR), which is active in the areas of drug development for cardiovascular and neurological diseases.
Veyonda is currently not approved in Australia or any other country